Fighting superbugs with ‘supercharged’ antibiotics

Existing antibiotics may be able to be improved by enhancing their ability to target and bind to drug-resistant bacteria.

Scientists at the University of Queensland in Australia are attacking antibiotics-resistant bacteria by teaching an old drug new tricks. The drug is the antibiotic vancomycin, and the team has early evidence that their revamped version could be used to treat methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE).

The scientists took vancomycin and re-engineered it to make it bind to the membranes of bacteria, rather than to human cells, according to a press release from the university. The technique resulted in a series of “supercharged” antibiotics, dubbed vancapticins.

The new molecules were active against vancomycin-resistant strains of bacteria in the lab, so the team went on to test the vancapticins in mouse models of multiple infections, they reported in the journal Nature Communications. They drugs were effective, unlikely to cause resistance, and exhibited a profile that could translate to once-daily dosing in people, they said.

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

RELATED: AMRC strikes deal to aid Russian antimicrobial research

Antibiotics resistance continues to raise concerns worldwide. In the U.S. alone, up to 2 million people become infected with drug-resistant bugs each year, and an estimated 23,000 people die because of a lack of effective treatments, according to the Centers for Disease Control.

The biotech industry has charted some progress in recent years, developing novel approaches to combating antibiotics resistance—and that has attracted the interest of investors. For example, San Diego-based Forge Therapeutics raised $15 million in a series A financing round last April to advance its antibiotics that target LpxC, a zinc metalloenzyme. In October, the company expanded a partnership with Evotec to accelerate the research.

Rather than developing entirely new compounds, the scientists at the University of Queensland saw potential in improving antibiotics that have already proven their value. "Drug development is normally focused on improving binding to a biological target, and rarely focuses on assessing membrane-binding properties,” said co-author Matt Cooper, a professor at the school’s Institute for Molecular Bioscience. His team figured that if they enhanced those properties, they could increase the amount of drug that hits the target bacteria, as well as improving the ability of drugs to selectively target superbugs, they said in their paper.

The team started with vancomycin because it is widely used to treat MRSA, a hospital-acquired infection that has become increasingly difficult to control because of drug resistance. But Cooper and his colleagues believe their approach could be used to revitalize many other existing antibiotics.

“Given the alarming rise of multi-drug resistant bacteria and the length of time it takes to develop a new antibiotic, we need to look at any solution that could fix the antibiotic drug discovery pipeline now,” Cooper said.

Suggested Articles

A COVID-19 antibody diagnostic developed through a joint venture between Mount Sinai Health System and RenalytixAI has been authorized by the FDA.

Researchers at Northwestern University have trained an AI algorithm to automatically detect the signs of COVID-19 on a basic X-ray of the lungs.

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.